Overview

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Phase:
Phase 3
Details
Lead Sponsor:
Arena Pharmaceuticals